1. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of
two parts). N Engl J Med 292(8):403–407
2. Burmester G-R, Buttgereit F (2001) Dermatomyositis – Polymyositis. In:
Zeidler H, Zacher J, Hiepe F, editors. Interdisziplinäre klinische Rheumatologie.
Springer, Berlin, S895–903
3. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body
myositis. N Engl J Med 325(21):1487–1498
4. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (First of two
parts). N Engl J Med 292(7):344–347
5. Catoggio LJ (2003) Connective Tissue Disorders: Inflammatory Muscle Disease.
Management. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME,
Weisman MH (eds) Rheumatology. Mosby, Edinburgh, pp 1555–1562
6. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al
(1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329(27):1993–2000
7. WHO technical report (1989) Requirements for the collection, processing, and quality control of blood, blood components, and plasma derivatives. WHO technical Report Series No 786:Annex 4
8. Berger A, Doerr HW, Scharrer I, Weber B (1997) Follow-up of four HIVinfected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C/HGV transmission. J Med Virol 53(1):25–30
9. Bjorkander J, Fasth A, Widell A (1996) Intravenous immunoglobulin and hepatitis C virus: the Scandinavian experience. Clin Ther 18:(Suppl B):73–82
10. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331(24):1607–1611
11. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ et al (1996) Hepatitis C virus infection associated with administration of intravenous immune globulin: A cohort study. JAMA 276(19):1563–1567
12. Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N et al (1997) Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 110(1):4–8
13. Flora K, Schiele M, Benner K, Montanaro A, Johnston W, Whitham R et al (1996) An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin. Ann Allergy Asthma Immunol 76(2):160–162
14. Gangneux JP, Traineau R, Tuveri R, Ravera N, Bureau C, Gluckman E et al (1996) Transmission of hepatitis C virus in allografted patients: use of viral genotyping as an epidemiological marker. Bone Marrow Transplant 18(6):1131–1133
15. Gomperts ED (1996) Gammagard and reported hepatitis C virus episodes. Clin Ther 18(Suppl B):3–8
16. Healey CJ, Sabharwal NK, Daub J, Davidson F, Yap PL, Fleming KA et al (1996) Outbreak of acute hepatitis C following the use of anti-hepatitis C virus-screened intravenous immunoglobulin therapy. Gastroenterology 110(4):1120–1126
17. Jonas MM, Baron MJ, Bresee JS, Schneider LC (1996) Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 98(2 (Pt 1):211–215
18. Lefrere JJ, Loiseau P, Martinot-Peignoux M, Mariotti M, Ravera N, Thauvin M et al (1996) Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion 36(5): 394–397
19. Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E (1997) Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 90(3): 1309–1314
20. Widell A, Zhang YY, Andersson-Gare B, Hammarstrom L (1997) At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulinassociated hepatitis C. Transfusion 37(3):313–320
21. Yap PL, McOmish F, Webster AD, Hammarstrom L, Smith CI, Bjorkander J et al (1994) Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 21(3):455–460
22. Ballow M (2002) Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc (Wash) 42(3):458–459
23. Dodd RY (1996) Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Clin Exp Immunol 104 (Suppl 1):31–34
24. Tabor E (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39:1160–1168
25. Barin F (2000) Viruses and unconventional transmissible agents: update on transmission via blood. Transfus Clin Biol 7 (Suppl 1):5S–10S
26. Will RG, Kimberlin RH (1998) Creutzfeldt-Jakob disease and the risk from blood or blood products. Vox Sang 75(3):178–180
27. Yap PL, Leaver HA, Gillon J (1998) Prions: properties, occurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Vox Sang 74(Suppl 2):131–134
28. Lacy CF, Armstrong LL, Goldman MP, Lance LL (2003) Drug Information Handbook, 11th ed. Hudson, Ohio, Lexi-Comp Inc
29. Schiff RI (1986) Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev Infect Dis 8 (Suppl 4):S449–S456
30. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M et al (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50(2):398–402
31. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349(9052):589–593
32. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and highdose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41(6):789–796
33. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315(6):341–347 H. Michels et al. 109 i.v.-Immunglobuline bei chronischen idiopathischen Myositiden
34. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639
35. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M et al (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50(5):1273–1281
36. van der Meché FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326(17):1123–1129
37. Dalakas MC (1996) Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 104 (Suppl 1):55–60
38. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345(10):747–755
39. Wittstock M, Benecke R, Zettl UK (2003) Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 50(3):172–175
40. Buckley RH, Schiff RI (1991) The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325(2):110–117
41. Bjorkander J, Hammarstrom L, Smith CI, Buckley RH, Cunningham-Rundles C, Hanson LA (1987) Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 7(1):8–15
42. Ahsan N, Palmer BF, Wheeler D, Greenlee RG Jr, Toto RD (1994) Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 154(17):1985–1987
43. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ (1995) Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 25(2):228–234
44. Stahl M, Schifferli JA (1998) The renal risks of high-dose intravenous immunoglobulin treatment [editorial]. Nephrol Dial Transplant 13(9): 2182–2185
45. US Food and Drug Administration. Important Drug Warning. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm105914.htm
46. Brox AG, Cournoyer D, Sternbach M, Spurll G (1987) Hemolytic anemia following intravenous gamma globulin administration. Am J Med 82 (Suppl 3):633–635
47. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM (1992) Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 120(6):926–928
48. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ (1986) Hemolysis following intravenous immune globulin therapy. Transfusion 26(5):410–412
49. Nakamura S, Yoshida T, Ohtake S, Matsuda T (1986) Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta Haematol; 76(2–3):115–118
50. Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121(4):259–262
51. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP (1996) Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47(3):674–677
52. Crouch ED, Watson LE (2002) Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura–a case report and literature review. Angiology 53(1):113–117
53. Elkayam O, Paran D, Milo R, Davidovitz Y, Almoznino-Sarafian D, Zeltser D et al (2000) Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 59(1):77–80
54. Emerson GG, Herndon CN, Sreih AG (2002) Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 22(12):1638–1641
55. FDA: FDA Interim Statement Regarding Immune Globulin Intravenous (IGIV). http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm195249.htm
56. Fisman DN, Smilovitch M (1997) Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 13(8):775–777
57. Go RS, Call TG (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75(1):83–85
58. Okuda D, Flaster M, Frey J, Sivakumar K (2003) Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 60(11):1825–1826 59. Struble EJ, Dice YG (2002) Intravenous immune globulin (IVIG) precipitating acute myocardial infarction. J Miss State Med Assoc 43(4):115
60. Zaidan R, Al Moallem M, Wani BA, Shameena AR, Al Tahan AR, Daif AK et al (2003) Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 10(4): 367–372
61. Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A et al (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirtyfive adult patients. Arthritis Rheum 46(2):467–474
62. Göttfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B (2000) High-dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10(1):29–35
63. Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M et al (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61(1):37–41 64. Soueidan SA, Dalakas MC (1993) Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43(5):876–879
65. Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S et al (2002) Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58(2):326
66. Mukunda BN, Dileep Kumar P, Smith HR (2001) Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis. Ann Intern Med 134(12):1156 (letter)
67. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT (1994) Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 44(8):1516–1518
68. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. Neurology 48(3):712–716
69. Dalakas MC, Koffman BM, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56(3):323–327
70. Walter MC, Lochmüller H, Töpfer M, Schlotter B, Reilich P, Schröder M et al (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebocontrolled study. J Neurol 247(1):22–28
71. Pelkonen PM, Jalanko HJ, Lantto RK, Makela AL, Pietikainen MA, Savolainen HA et al (1994) Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol 21(11): 2143–2146
72. Downey ECJr, Woolley MM, Hanson V (1988) Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg 123(9):1117–1120
73. Miller LC, Michael AF, Kim Y (1987) Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila) 26(11):561–566
74. Pachman LM (1990) Juvenile dermatomyositis: a clinical overview. Pediatrics
in Review 12(4):117–125
75. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43(3): 541–549
76. Quecedo E, Febrer I, Serrano G, Martinez-Aparicio A, Aliaga A (1996) Partial lipodystrophy associated with juvenile dermatomyositis: report of two cases. Pediatr Dermatol 13(6): 477–482
77. Galeazzi M, Bellucci AM, Girardelli CR, Bono R, De Pita O, Puddu P (1996) Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis. Clin Rheumatol 15(2):215–216
78. Kokori H, Fotoulaki M, Giannakopoulou C, Hatzidaki E, Tantros S, Sbyrakis S (1999) Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis. Pediatr Int 41(6):696–697
79. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW (1987) Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 258(4):513–515
80. Breems DA, de Haas PW, Visscher F, Sabbe LJ, Busch HF, van Doorn PA (1993) Intravenously-administered immunoglobulin as first-choice agent in juvenile dermatomyositis. Ned Tijdschr Geneeskd 137(39):1979–1982
81. Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D (1994) Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 130(2):231–234
82. Morita R, Nakano K, Hirano Y, Izumi T, Hirayama Y, Suzuki H et al (1989) Dramatic effects of high-dose intravenous gammaglobulin in each patient with intractable dermatomyositis and polymyositis. No To Hattatsu 21(6):523–528
83. Schmidt K, Westenberger-Treumann M, Stadler R (1994) High dosage intravenous gamma globulin therapy in juvenile dermatomyositis. Hautarzt 45(12):854–857
84. Vedanarayanan V, Subramony SH, Ray LI, Evans OB (1995) Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin. Pediatr Neurol 13(4):336–339
85. Zifko U, Grisold W (1995) Dermatomyositis: Erfolgreiche Therapie mit hochdosierten intravenös applizierten 7S-Immunoglobulinen. Wien Klin Wochenschr 107(17):522–524
86. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM (1991) Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91(2):169–172
87. Samsone A, Dubowitz V (1995) Intravenous immunoglobulin in juvenile dermatomyositis – four year review of nine cases. Arch Dis Child 72(1): 25–28
88. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27(10):2498–2503
89. Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51 (Suppl 5)(6 Suppl 5):S37–S45.